Research Institute of Molecular Pathology IMP
Funded primarily by Boehringer Ingelheim and with unconstrained academic freedom, the Research Institute of Molecular Pathology (IMP) is a leading institute for biomedical researchin Vienna, Austria.
Search
Vaccines
Vaccines
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Oncology Translational Science
Discover how Boehringer Ingelheim leverages translational science to bridge pre-clinical research and clinical development, enhancing patient outcomes in oncology. Learn about our patient-centric strategies, biomarker discovery, and collaborative efforts
Boehringer Ingelheim Office Hours 2024: Shaping the Future of Innovation in Europe
Boehringer Ingelheim is actively supporting the next generation of innovators.
Fact & Figures Boehringer Ingelheim RCV
Facts and figures speak a clear language. Only economic success enables us to implement our corporate vision.
Small Molecule Drug Discovery
Boehringer Ingelheim scientists continue to expand the horizons of what small molecule drugs can achieve.
Unleashing Innovation at Boehringer Ingelheim
Join us at our upcoming seminar and networking event where we'll share our unique approach to fostering innovation and supporting startups. We're excited to introduce you to Research Beyond Borders, our approach to open science: opnMe.com
Biotherapeutics Discovery
Our committed team of scientists are using all their experience and knowledge to forge new research paths, engineer new molecules and do whatever it takes to make sure that no patient is left behind in our search for the next breakthrough.
Open Innovation Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Boehringer Ingelheim’s Postdoctoral Program
Boehringer Ingelheim’s postdoctoral program in Regional Center Vienna (RCV) provides scientists with the opportunity to pursue research.
Testing New Treatments for NF1
The Medical University of Vienna and Boehringer Ingelheim have taken an innovative approach to the development of ways of treating NF1-associated tumors.
Data Science: Revolutionizing research and development with data driven insights
Using data in pharmaceutical research to better address patient needs
About Our Innovation Prize
Celebrating Our Innovation Prize Winners
Interstitial Lung Diseases - Sound the ILD Alarm
Learn more about ILDs and why it's important to ‘sound the ILD alarm’ for early detection and treatment.
Making sustainable medicines through eco-design
Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle